ecrin-mdr-crcClinical2005SarcomaCarcinoma, Non-Small-Cell LungLung cancerColorectal cancerMesotheliomaBreast cancerBladder cancerNeoplasmsOvarian cancerThyroid cancerEsophageal NeoplasmsAdvanced Solid tumorHead and neck cancerTumorLung neoplasmsLung CancerSarcomaColorectal CancerMesotheliomaBladder CancerBreast CancerLung NeoplasmsNeoplasmsOvarian CancerEsophageal NeoplasmsThyroid CancerAdvanced Solid TumorTumorCarcinoma, Non-small-cell LungHead And Neck CancerInterventionalhttps://newmdr.ecrin.org/Study/2035464United States9ChondrosarcomaThyroid NeoplasmsBladder neoplasmsFibrosarcomaPXD101Mesothelioma, cysticCoin Lesion, PulmonaryOsteosarcomaCarcinoma, Small CellBelinostatMyosarcomaPulmonary Sclerosing HemangiomaFacial NeoplasmsAdenosarcomaPhyllodes TumorFluorouracilMyxosarcomaCarcinoma, BronchogenicParathyroid NeoplasmsCarcinosarcomaHemangiosarcomaOtorhinolaryngologic NeoplasmsHistiocytoma, Malignant FibrousMouth NeoplasmsPancoast’s SyndromeMixed Tumor, MesodermalLymphangiosarcomaLiposarcomaLeiomyosarcomaKidney cancerAndrogen-independent prostate cancerTracheal NeoplasmsECRIN MDRCompletedfalseStudy of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid TumorsThis is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).2005-09-152035464NCT00413322